sevenspikes.themes.common.filters
sevenspikes.themes.common.closemenu

西格玛

点此→【联络技术支持与销售】

西格玛 [Sigma-Aldrich]:美国西格玛sigma-aldrich是全球最大的化工试剂生产商,借助首要品牌:Merck,密理博Millipore,Milli-Q,色谱科Supelco,Fluka,SAFC,BioReliance,罗氏Roche、Avanti、Polar Lipids、Duolink等,Sigma-Aldrich是一家在生命科学与化学试剂行业领先的高科技企业。我们的生化试剂,化学试剂和试剂盒广泛应用于基因组学研究,药物研发,疾病诊断和化工生产上。客户遍及生命科学公司,大学,研究机构,医院以及工业部门。覆盖160多个国家,并在43个国家设有分支机构,雇员超过12,800人。

我们为科学家和工程师提供一流的实验室材料,技术和服务。 通过2015年默克密理博(Merck Millipore)和西格玛奥德里奇(Sigma-Aldrich)的合并,我们现在拥有超过300,000种产品的广泛投资组合,并扩大了全球业务覆盖范围。我们是全球生命科学行业领先的供应商:提供在生物技术和药物治疗研究方面:开发和生产方面的服务和解决方案。我们的目的是通过与全球科学界合作来解决生命科学中最棘手的问题,并以此为目标,促使世界各地的人们获得更好的健康和安全。我们致力于使科学研究和生物技术生产变得更简单,更快捷和更安全。

【默克与Sigma-Aldrich中国总代理:北实纵横科学公司】

默克密理博与默克西格玛SIGMA-ALDRICH


Sigma-Aldrich is a leading Life Science and High Technology company. Our chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostic and other high technology manufacturing.


默克西格玛 Life Science Business

SIGMA-ALDRICH


默克密理博 Merck Millipore: A Leader in Life Science

默克密理博与默克西格玛merck与sigma-aldrich
默克密理博与默克西格玛merck与sigma-aldrich
默克密理博与默克西格玛merck与sigma-aldrich

Merck Sigma-Aldrich® Corporation

默克与西格玛阿尔德里奇

When changing trends in chemical research confirmed the synergy to be realized from their complementary product offerings (approximately 40,000 in total at the time), Aldrich Chemical Co. merged with Sigma International, Ltd. to form Sigma-Aldrich Corporation in 1975. With this marriage of broad capabilities and resources, annual double-digit growth would become the standard in the 1980s and 1990s, with significant expansion in facilities, major acquisitions and ventures into new market sectors paving the way into the 21st century.

Sigma-Aldrich's international expansion took off in the 1980s with the opening of subsidiaries in France, Belgium, Japan, Italy, Netherlands and Spain. The acquisition of Biomakor in Israel in 1986 and Fluka in 1989 in Switzerland strengthened this rapid expansion. Sigma-Aldrich continued to increase its international presence greatly during the 1990s, opening 20 offices during that decade either by acquisition or by establishing a subsidiary. In Scandinavia, Sigma-Aldrich acquired four of its dealers, which became Sigma-Aldrich Sweden, Norway, Finland and Denmark. Following the fall of the Berlin Wall, the Company took advantage of the opening of these new markets by opening subsidiaries in Poland, Czech Republic, Hungary and by acquiring a dealer in Russia. Beginning to establish a presence in the area now known as CAPLA (Canada, Asia Pacific and Latin America), Sigma-Aldrich opened offices and distribution warehouses in Australia, followed by India, South Korea, Singapore and Malaysia, as well as Canada, Mexico, Brazil and Argentina in the Americas. This was only the beginning.

From the acquisiton of Supelco in 1993 and Riedel de Haen in 1997, each increasing Sigma-Aldrich's analytical and chromatography capabilities, the Company continued its growth strategy. The year 1999 brought with it the Company's first strategic plan, with Davd Harvey now at the helm as CEO, taking over for Tom Cori. By the next year, Sigma-Aldrich hit the $1 billion in sales milestone, with 6,000 employees in 33 countries – well-known and trusted worldwide.

In 2001, Sigma-Aldrich acquired Isotec, a leader in stable isotope production whose products are used in basic research and the diagnosis of disease. That same year, the Company opened its $55 million Life Science and High Technology Center in St. Louis. In 2004, Ultrafine, a supplier of contract manufacturing services for drug development, and Tetrionics, a producer of high potency and cytotoxic active pharmaceutical ingredients, became a strategic piece of the Company's portfolio. The following year, Sigma-Aldrich underwent its second strageic plan review, announcing the formation of four customer-centric business units and a strong focus on geographic expansion, Internet sales and process improvement to propel the Company to even greater heights. Jai Nagarkatti, former president of Aldrich, then became president and CEO of Sigma-Aldrich.

Sigma-Aldrich acquired JRH Biosciences (now SAFC Biosciences), a major industrial supplier of cell culture products for the pharmaceutical and biotechnology industries, and the Proligo Group, a global supplier of key genomics research tools. Also in 2005, Sigma-Aldrich announced membership in The RNAi Consortium and joined leading institutions including MIT, Harvard, and Eli Lilly to develop and distribute genome-wide shRNA libraries globally.

Sigma-Aldrich once again increased its global reach through the acquisitions of Beijing Superior Chemicals and Instruments Co. in China, Iropharm in Ireland, and Pharmorphix Ltd. in the UK. Other strategic acquistions would soon follow: Epichem Group Ltd. to expand capabilities in materials sciences and semiconductor markets, and Molecular Medicine BioServices to provide large-scale viral manufacturing capabilities.

In 2007, Sigma-Aldrich achieved another significant milestone by exceeding $2 billion in sales, delivering record earnings and further strengthening its leadership in the markets it serves. The strategic plan was proving to be quite successful, paving the way for a renewed focus the following year through the Company's third strategic plan.

More recently, Sigma-Aldrich acquired ChemNavigator in 2009 to provide researchers with industry-leading chemical compound selection and procurement services. That same year, the Company introduced CompoZr™ Zinc Finger Technology and Sigma Advanced Genetic Engineering (SAGE™) Labs to offer next-generation rodent research models that can provide new insight into human disease. Sage Labs' targeted knockout rat ranked among The Scientist magazine's top five innovations of 2009.

In the decades since the 1975 merger, the Company has generated exceptional growth and continues to undergo many positive changes to drive Sigma-Aldrich into the future of science and technology. One such change has been the rise of the Internet and e-commerce, now accounting for approximately 45% of all research sales to become the Company's most powerful marketing tool. In addition, as Sigma-Aldrich continually increases its global reach, approximately 65% of sales stem from outside of the U.S.

Our future success requires more innovative products, faster technologies, and more sophisticated tools that support our customers' success. To accomplish this, our Company has new strategic initiatives that are expected to drive innovation and expand into new markets by leveraging our core scientific strengths: Analytical Chemistry, Biology, and Chemistry-Materials Science (ABCM). Our ABCM initiatives will help us expand our product offering, open new markets and enhance our position in the areas we know best.

Today, Sigma-Aldrich has a broad offering of more than 147,000 chemical products (48,000 of which the Company manufactures) and 40,000 equipment items. We supply products to customers in over 150 countries around the world through state-of-the-art distribution centers. With a committed workforce of approximately 8,000 employees in 40 countries, Sigma-Aldrich has the unrivalled scientific knowledge, unsurpassed service, and global reach to serve researchers and technologists and to ultimately improve quality of life.

Merck KGaA, Darmstadt, Germany and/or its affiliates.